序号 |
标题 |
次数 |
作者 |
发布时间 |
77086 |
DOTA-(Tyr3)-octreotate,204318-14-9,类似奥曲肽的多肽 |
107 |
h |
2024-12-11 |
77087 |
Edotreotide(DOTATOC),生长抑素类似物 |
129 |
h |
2024-12-11 |
77088 |
p-SCN-Bn-DOTA,127985-74-4,可用于标记多肽 |
120 |
h |
2024-12-11 |
77089 |
PAMAM-PEG-DOTA-Gd,聚酰胺-胺聚乙二醇DOTA钆 |
93 |
h |
2024-12-11 |
77090 |
螯合剂多肽,cyclo(RGDFK(DOTA)) |
128 |
h |
2024-12-11 |
77091 |
质粒构建的原理及方法 |
505 |
axc |
2024-12-11 |
77092 |
什么是基因过表达(gene overexpression) |
1003 |
axc |
2024-12-11 |
77093 |
m-PEG6-(CH2)6-phosphonic acid,cas:2028284-71-9 |
104 |
zcy |
2024-12-11 |
77094 |
1201415-84-0,1180007-00-4,DOTA-Lys-Cys-COOH |
84 |
h |
2024-12-11 |
77095 |
CRISPR/Cas9系统基因敲除个别外显子(操作步骤) |
470 |
axc |
2024-12-11 |
77096 |
大环螯合物DOTA,DOTA-RGD |
80 |
h |
2024-12-11 |
77097 |
BocNH-O-(CH₂)₅-COOH BOC 保护基-氨基-五碳链-羧酸 |
137 |
zcy |
2024-12-11 |
77098 |
基因敲除方法,基因敲除小鼠定制服务 |
183 |
axc |
2024-12-11 |
77099 |
"Maleimide-(CH2)5-COONHS cas:55750-63-5 6-(马来酰亚胺基)己酸琥珀酰亚胺酯" |
102 |
zcy |
2024-12-11 |
77100 |
质粒构建的原理、步骤|质粒构建定制服务 |
419 |
axc |
2024-12-11 |
77101 |
DOTA-「Tyr3」-Octreotide,Edotreotide,奥曲肽的多肽 |
133 |
h |
2024-12-11 |
77102 |
Mal-PEG-CH2CO2H(马来酰亚胺) |
98 |
WYQ |
2024-12-11 |
77103 |
Stearic acid-PEG-CH2CO2H |
127 |
WYQ |
2024-12-11 |
77104 |
Dotatate,DOTA-奥曲肽 |
133 |
h |
2024-12-11 |
77105 |
螯合剂多肽DOTA-cyclo(RGDfK) |
110 |
h |
2024-12-11 |
77106 |
Biotin-PEG-CH2CO2H(生物素)(聚乙二醇)(甲基羧酸) |
150 |
WYQ |
2024-12-11 |
77107 |
Pomalidomide-PEG4-CH2COOH (CAS: 2097938-44-6) |
93 |
WYQ |
2024-12-11 |
77108 |
Pomalidomide-PEG2-CH2COOH (CAS: 2143097-05-4) |
96 |
WYQ |
2024-12-11 |
77109 |
Hydroxy-PEG1-CH2-Boc |
109 |
kx |
2024-12-11 |
77110 |
Thalidomide-O-PEG2-CH2-Ald (CAS: 2286368-58-7) |
138 |
WYQ |
2024-12-11 |
77111 |
双功能螯合剂DOTA-多肽;DOTA-cRGD 大环螯合剂修饰靶向环肽 |
105 |
h |
2024-12-11 |
77112 |
DSPE-PEG-CH2COOH(CAS: 474922-20-8) |
138 |
WYQ |
2024-12-11 |
77113 |
质粒构建的过程,制备方法 |
293 |
axc |
2024-12-11 |
77114 |
Tos-PEG1-CH2-Boc的应用和用途 |
130 |
kx |
2024-12-11 |
77115 |
204318-14-9,DOTA-(Tyr3)-octreotate,依多曲肽 |
74 |
h |
2024-12-11 |
77116 |
"Maleimide-(CH2)2-COOH cas:7423-55-4 3-马来酰亚胺基丙酸" |
158 |
zcy |
2024-12-11 |
77117 |
Propargyl-PEG3-CH2CO2H |
137 |
WYQ |
2024-12-11 |
77118 |
DOTA多肽分子探针,619300-53-7 |
111 |
h |
2024-12-11 |
77119 |
t-Boc-Aminooxy-PEG2-CH2CO2tBu(CAS: 2100306-57-6) |
83 |
WYQ |
2024-12-11 |
77120 |
β-NF-CH2-OH |
131 |
kx |
2024-12-11 |
77121 |
PEG5-(CH2CO2t-Butyl)2(CAS: 211746-78-0) |
120 |
WYQ |
2024-12-11 |
77122 |
Hydroxy-PEG4-CH2-Boc |
156 |
kx |
2024-12-11 |
77123 |
PEG6-(CH2CO2t-Butyl)2(CAS: 211746-79-1) |
128 |
WYQ |
2024-12-11 |
77124 |
七肽DOTA-YLYEIAR,1262403-91-7 |
112 |
h |
2024-12-11 |
77125 |
质粒构建的原理与类型 |
149 |
axc |
2024-12-11 |
77126 |
Thalidomide-5-NH2-CH2-COOH |
122 |
kx |
2024-12-11 |
77127 |
Cbz-N-Amido-PEG4-CH2COOH(CAS: 1451362-51-8) |
138 |
WYQ |
2024-12-11 |
77128 |
HO-PEG10-CH2COOtBu |
89 |
|
2024-12-11 |
77129 |
t-butyl ester-PEG4-CH2COOH (CAS: 929087-83-2) |
141 |
WYQ |
2024-12-11 |
77130 |
什么是载体构建与质粒构建 |
198 |
axc |
2024-12-11 |